Oncology blockbusters must target adjuvant settings to secure massive patient volumes.
Facing crowded markets and high clinical failure rates in metastatic cancers, drugmakers are shifting clinical development to post-surgical adjuvant settings with longer treatment windows and larger patient pools.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The milestone Phase 3 victory for the personalized mRNA vaccine was achieved specifically within the post-surgical adjuvant setting for melanoma.
A drug developer is expanding its oncology franchise from metastatic disease into post-surgical adjuvant therapy to target patients at earlier stages.
Moderna and Merck successfully validated their individualized neoantigen therapy by targeting patients in the high-volume adjuvant setting.
An investigational mRNA neoantigen therapy demonstrated clinical success specifically in the post-surgical adjuvant setting.
Following a failure in the metastatic setting, the developer redirected its regulatory and commercial strategy to target the far more lucrative early-stage adjuvant market.
Shifting the clinical focus of these blocking agents to early-stage adjuvant settings vastly expands candidate eligibility and treatment durations.
By moving Pluvicto earlier into the prostate cancer disease continuum, Novartis successfully expanded its eligible patient volume.
Oncology blockbusters are combining targeted therapeutics to establish superior clinical benefit in the post-surgical adjuvant setting, maximizing early patient market volumes.